The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of durvalumab (D) with or without tremelimumab (T) in routine clinical practice according to HIMALAYA trial eligibility: Preliminary results of the international DT-real study.
 
Ciro Celsa
Consulting or Advisory Role - Eisai Europe; MSD
Speakers' Bureau - AstraZeneca; Eisai; MSD
Travel, Accommodations, Expenses - Roche
 
Naoshi Nishida
No Relationships to Disclose
 
Shadi Chamseddine
No Relationships to Disclose
 
Ashwini Arvind
No Relationships to Disclose
 
Michael Li
No Relationships to Disclose
 
Hidenori Toyoda
Honoraria - Abbvie; AstraZeneca; Eisai; Fujifilm; Gilead Sciences; Kowa Pharmaceutical; Takeda; TERUMO
 
Susanna Ulahannan
Consulting or Advisory Role - AstraZeneca; Eisai; IgM Biosciences
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Artios (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Eisai (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); Exthera medical (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); immunitas (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Omega Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Purple Biotech (Inst); Qurgen (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sapience Therapeutics (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Theradex (Inst); Totus Medicines (Inst); Tvardi Therapeutics (Inst); Tvardi Therapeutics (Inst); Vigeo Therapeutics (Inst)
 
Claudia Fulgenzi
No Relationships to Disclose
 
Giulia Manfredi
No Relationships to Disclose
 
Antonio D'Alessio
Consulting or Advisory Role - Roche
Speakers' Bureau - AstraZeneca; Chugai/Roche; Eisai; Roche
Travel, Accommodations, Expenses - Roche
 
Bernardo Stefanini
No Relationships to Disclose
 
Giuseppe Cabibbo
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Ipsen; MSD; Roche
 
Calogero Cammà
Consulting or Advisory Role - AstraZeneca; Eisai; Ipsen; MSD; Roche
 
Bernhard Scheiner
No Relationships to Disclose
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb Italy; Eisai; Gilead Sciences; Guerbet; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Eisai; Eisai; Elevar Therapeutics; Exelixis; Genenta Science; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks
Research Funding - Abbvie (Inst); Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; SERVIER (Inst); Taiho Oncology (Inst); TransThera Sciences (Nanjing), Inc. (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); GlaxoSmithKline; J-Pharma; Jazz Pharmaceuticals; Kinnate Biopharma; Merck (Inst); Moderna Therapeutics; Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
 
Amit Singal
Consulting or Advisory Role - Arcus therapeutics; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Exelixis; Merck; Pfizer; Xilio therapeutics
Research Funding - Abbvie (Inst)
 
Ahmed Kaseb
Honoraria - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
David Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Lift Biosciences; Mursla Bio; Roche/Genentech; Starpharma
Consulting or Advisory Role - AstraZeneca; Da Volterra; EISAI; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology (Inst)